Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide

Journal of Acquired Immune Deficiency Syndromes

Volumn 48, Issue 5, 2008, Pages 572-576

  Marconi, Vincent ^a,d   Bonhoeffer, Sebastian ^b   Paredes, Roger ^a   Lu, Jing ^a   Hoh, Rebecca ^c   Martin, Jeffery N ^c   Deeks, Steven G ^c   Kuritzkes, Daniel R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ETH ZURICH   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

Allele specific PCR; Enfuvirtide; HIV 1; Treatment interruption; Viral dynamics; Viral fitness

Indexed keywords

ENFUVIRTIDE; GLYCOPROTEIN GP 41; VIRUS RNA; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PEPTIDE FRAGMENT;

ALLELE; ANTIVIRAL RESISTANCE; ARTICLE; DRUG PULSE THERAPY; DRUG WITHDRAWAL; GENE SEQUENCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VIVO STUDY; MUTANT; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REBOUND; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS MUTATION; VIRUS REPLICATION; WILD TYPE; BLOOD; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; PHYSIOLOGY; VIROLOGY; VIRUS LOAD;

DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; PEPTIDE FRAGMENTS; VIRAL LOAD;

EID: 50949118572     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31817bbc4e     Document Type: Article

References (21)

1. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175-2185.
2. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186-2195.
3. Sista PR, Melby T, Davison D, et al. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS. 2004;18:1787-1794.
4. Lu J, Deeks SG, Hoh R, et al. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of clonal analysis. J Acquir Immune Defic Syndr. 2006;43:60-64.
5. Marcelin AG, Reynes J, Yerly S, et al. Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20. AIDS. 2004;18:1340-1342.
6. Lu J, Sista P, Giguel F, et al. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol. 2004;78:4628-4637.
7. Deeks SG, Lu J, Hoh R, et al. Interruption of enfuvirtide in HIV-1-infected adults with incomplete viral suppression on an enfuvirtide-based regimen. J Infect Dis. 2007;195:387-391.
8. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187:1534-1543.
9. Aquaro S, D'Arrigo R, Svicher V, et al. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J Antimicrob Chemother. 2006;58:714-722.
10. Melby TE, Despirito M, Demasi RA, et al. Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy. AIDS. 2007;21:253-259.
11. Paredes R, Marconi VC, Campbell TB, et al. Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations. J Virol Methods. 2007;146: 136-146.
12. Bonhoeffer S, Barbour AD, de Boer RJ. Procedures for reliable estimation of viral fitness from time-series data. Proc R Soc Lond B Biol Sci. 2002; 269:1887-1893.
13. Bonhoeffer S, Funk GA, Gunthard HF, et al. Glancing behind virus load variation in HIV-1 infection. Trends Microbiol. 2003;11: 499-504.
14. Murphy DG, Fauvel M, Rene P, et al. Multicenter comparison of Roche COBAS AMPLICOR MONITOR version 1.5, Organon Teknika NucliSens QT with Extractor, and Bayer Quantiplex version 3.0 for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 2000;38:4034-4041.
15. McLean AR, Nowak MA. Competition between zidovudine-sensitive and zidovudine-resistant strains of HIV. AIDS. 1992;6:71-79.
16. Bonhoeffer S, Coffin JM, Nowak MA. Human immunodeficiency virus drug therapy and virus load. J Virol. 1997;71:3275-3278.
17. Derdeyn CA, Kilby M, Diego Miralles G, et al. Evaluation of distinct blood lymphocyte populations in human immunodeficiency virus type 1-infected subjects in the absence or presence of effective therapy. J Infect Dis. 1999;180:1851-1862.
18. Lambotte O, Chaix ML, Gubler B, et al. The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS. 2004;18:1147-1158.
19. Izopet J, Souyris C, Hance A, et al. Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype. J Infect Dis. 2002; 185:1506-1510.
20. Palmer S, Boltz V, Maldarelli F, et al. Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS. 2006;20:701-710.
21. Labrosse B, Morand-Joubert L, Goubard A, et al. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J Virol. 2006;80:8807-8819.